Hyzetimibe

Drug Profile

Hyzetimibe

Alternative Names: HS-25

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Zhejiang Hisun Pharmaceutical
  • Class Antihyperlipidaemics
  • Mechanism of Action Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypercholesterolaemia
  • No development reported Hyperlipidaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hyperlipidaemia in USA (PO)
  • 01 Dec 2014 Zhejiang Hisun Pharmaceutical completes a phase II trial in Hypercholesterolaemia in USA (NCT02087917)
  • 14 Mar 2014 Zhejiang Hisun Pharmaceutical plans a phase II trial for primary Hypercholesterolaemia in USA (NCT02087917)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top